Brokerages Anticipate Corbus Pharmaceuticals Holdings Inc (CRBP) Will Post Quarterly Sales of $1.66 Million

Equities analysts expect that Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) will post $1.66 million in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Corbus Pharmaceuticals’ earnings. The highest sales estimate is $1.90 million and the lowest is $1.28 million. Corbus Pharmaceuticals posted sales of $800,000.00 in the same quarter last year, which would indicate a positive year over year growth rate of 107.5%. The company is expected to issue its next quarterly earnings results before the market opens on Thursday, November 8th.

On average, analysts expect that Corbus Pharmaceuticals will report full-year sales of $5.74 million for the current financial year, with estimates ranging from $5.38 million to $6.25 million. For the next year, analysts expect that the business will post sales of $9.09 million, with estimates ranging from $7.16 million to $12.50 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Corbus Pharmaceuticals.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.01. The company had revenue of $0.85 million during the quarter, compared to the consensus estimate of $1.90 million.

Several equities research analysts recently commented on CRBP shares. BidaskClub raised shares of Corbus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, July 10th. Cantor Fitzgerald set a $32.00 price objective on shares of Corbus Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, July 25th. Finally, ValuEngine raised shares of Corbus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. One analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $25.50.

A number of large investors have recently modified their holdings of the business. Cambridge Investment Research Advisors Inc. lifted its position in Corbus Pharmaceuticals by 52.7% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 35,884 shares of the biopharmaceutical company’s stock worth $271,000 after buying an additional 12,380 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in Corbus Pharmaceuticals by 13.1% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 109,573 shares of the biopharmaceutical company’s stock worth $554,000 after buying an additional 12,700 shares in the last quarter. Alps Advisors Inc. lifted its position in Corbus Pharmaceuticals by 22.1% during the 3rd quarter. Alps Advisors Inc. now owns 101,232 shares of the biopharmaceutical company’s stock worth $764,000 after buying an additional 18,305 shares in the last quarter. Allianz Asset Management GmbH lifted its position in Corbus Pharmaceuticals by 15.8% during the 1st quarter. Allianz Asset Management GmbH now owns 137,624 shares of the biopharmaceutical company’s stock worth $840,000 after buying an additional 18,778 shares in the last quarter. Finally, Barclays PLC lifted its position in Corbus Pharmaceuticals by 237.5% during the 1st quarter. Barclays PLC now owns 28,302 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 19,917 shares in the last quarter. 42.69% of the stock is currently owned by hedge funds and other institutional investors.

CRBP traded up $0.40 during trading on Friday, hitting $7.70. The company had a trading volume of 100,397 shares, compared to its average volume of 1,143,557. The stock has a market capitalization of $416.46 million, a P/E ratio of -11.77 and a beta of 2.16. Corbus Pharmaceuticals has a one year low of $4.50 and a one year high of $9.95.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes.

See Also: Bond

Get a free copy of the Zacks research report on Corbus Pharmaceuticals (CRBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply